MetaCap

Gyre Therapeutics (GYRE) vs Monopar Therapeutics (MNPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Monopar Therapeutics (MNPR) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 24.6% versus a loss of 44.2%. Over five years, MNPR leads with a +184.5% price change compared with -77.5% for GYRE. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $460.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GYRE-44.24%MNPR-24.64%
+39%-6%-51%
Nov 21, 20251 yearNov 20, 2026
GYRE-78.58%MNPR+192.99%
+431%+156%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GYRE versus MNPR key metrics
MetricGYREMNPR
Share price$4.21$69.00
Market cap$460.79M$467.60M
1-day change-6.86%-1.84%
YTD return-40.37%+5.67%
1-year return-44.24%-24.64%
5-year return-77.55%+184.54%
Forward P/E70.17—
EPS (TTM)$-0.31$-2.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$116.59M$0
Revenue growth (YoY)+10.24%—
Net income (latest FY)$9.88M$-13.72M
Gross margin95.35%—
Operating margin9.85%—
Net margin8.47%—
52-week high$9.14$124.82
52-week low$3.97$50.07
Distance from 52-week high-53.94%-44.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+343.47%+88.65%
Average volume181.04K151.83K
Shares outstanding109.45M6.78M
Employees62522
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNPR has outperformed GYRE by 19.6 percentage points over the past year.

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

GYRE vs MNPR FAQ

Which is bigger, Gyre Therapeutics or Monopar Therapeutics?

Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $460.79M for Gyre Therapeutics (GYRE).

Which stock has performed better over the past year, GYRE or MNPR?

MNPR returned -24.64% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.

Are Gyre Therapeutics and Monopar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons